Antiproliferative effect on HepaRG cell cultures of new calix[4]arenes. Part II

References

• Brittenham, GM. Disorders of iron metabolism: iron deficiency and overload. In: Hoffman R, Benz EJ, Shattil SJ, Furie B, Cohen HJ, et al., eds. Hematology: Basic Principles and Practise, 3rd ed New York; Churchill Livingstone, 2000:397–428.
   Google Scholar
• McCance RA, Widdowson EM. Absorption and excretion of iron. Lancet 1937;ii:680–684.
   Google Scholar
• Deugnier Y, Charalambous P, Le Quilleuc D, Turlin B, Searle J, Brissot P, Powell LW, Halliday JW. Preneoplastic significance of hepatic iron-free foci in genetic hemochromatosis: a study of 185 patients. Hepatology 1993;18:1363–1369.
   PubMed Web of Science ®Google Scholar
• Hsing AW, McLaughlin JK, Olsen JH, Mellemkjar L, Wacholder S, Fraumeni JF. Cancer risk following primary hemochromatosis: a population-based cohort study in Denmark. Int J Cancer 1995;60:160–162.
   PubMed Web of Science ®Google Scholar
• Andrews NC. Disorders of iron metabolism. N Engl J Med 1999;341:1986–1995.
   PubMed Web of Science ®Google Scholar
• Kalinowski DS, Richardson DR, The evolution of iron chelators for the treatment of iron overload disease and cancer. Pharmacol Rev 2005;57:547–583.
   PubMed Web of Science ®Google Scholar
• Soyano A, Chinea M, Romano EL. The effect of desferrioxamine on the proliferative response of rat lymphocytes stimulated with various mitogens in vitro. Immunopharmacol 1984;8:163–169.
   PubMed Web of Science ®Google Scholar
• Polson RJ, Jenkins R, Lombard M, Williams AC, Roberts S, Nouri-Aria K, Williams R, Bomford A. Mechanisms of inhibition of mononuclear cell activation by the iron-chelating agent desferrioxamine. Immunology 1990;71:176–181.
   PubMed Web of Science ®Google Scholar
• Richardson DR, Milnes K. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents II: the mechanism of action of ligands derived from salicylaldehyde benzoyl hydrazone and 2-hydroxy-1-naphthylaldehyde benzoyl hydrazone. Blood 1997;89:3025–3038.
   PubMed Web of Science ®Google Scholar
• Chenoufi N, Baffet G, Drénou B, Cariou S, Desille M, Clément B, Brissot P, Lescoat G, Loréal O. Deferoxamine arrests in vitro the proliferation of porcine hepatocyte in G1 phase of the cell cycle. Liver 1997;18:60–67.
   Google Scholar
• Rakba N, Loyer P, Gilot D, Delcros JG, Glaise D, Baret P, Pierre JL, Brissot P, Lescoat G. Antiproliferative and apoptotic effects of O-Trensox, a new synthetic iron chelator, on differentiated human hepatoma cell lines. Carcinogenesis 2000;21:943–51.
   PubMed Web of Science ®Google Scholar
• Richardson DR. Potential of iron chelators as effective antiproliferative agents. Can J Physiol Pharmacol 1997;75:1164–1180.
   PubMed Web of Science ®Google Scholar
• Hann HWL, Stahlhut MW, Blumberg BS. Iron mutation and tumor growth: decreased tumor growth in iron deficient mice. Cancer Res 1988;48:4168–4170.
   PubMed Web of Science ®Google Scholar
• Le NTV, Richardson DR, The role of iron in cell cycle progression and the proliferation of neoplastic cells. Biochim Biophys Acta 2002;1603:31–46.
   PubMed Web of Science ®Google Scholar
• Chaston TB, Richardson DR. Iron chelators for the treatment of iron overload disease: relationship between structure, redox activity and toxicity. Am J of Hematology 2003;73:200–210.
   PubMed Web of Science ®Google Scholar
• Richardson DR. Iron chelators as therapeutic agents for the treatment of cancer. Crit Rev Oncol/Hematol 2002;42:267–281.
   PubMed Web of Science ®Google Scholar
• Richardson DR, Sharpe PC, Lovejoy DB, Senaratne D, Kalinowski DS, Islam M, Bernhardt PV. Dipyridyl thiosemicarbazone chelators with potent and selective antitumor activity form iron complexes with redox activity. J Med Chem 2006;49:6510–6521.
   PubMed Web of Science ®Google Scholar
• Gao J, Richardson DR. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents: IV. The mechanisms involved in inhibiting cell-cycle progression. Blood 2001;98:842–850.
   PubMed Web of Science ®Google Scholar
• Finch RA, Liu M, Grill SP, Rose WC, Loomis R, Vasquez KM, Cheng Y, Sartorelli AC. Triapine (3-aminopyridine-2-carboxaldehyde-thiosemicarbazone):a potent inhibitor of ribonucleotide reductase activity with broad spectrum antitumor activity. Biochem Pharmacol 2000;59:938–91.
   Web of Science ®Google Scholar
• Brodie C, Siriwardana G, Lucas J, Schleicher R, Terada N, Szepesi A, Gelfand E, Seligman P. Neuroblastoma sensitivity to growth inhibition by desferrioxamine: evidence for a block in G1 phase of the cell cycle. Cancer Res 1993;53:3968–3975.
   PubMed Web of Science ®Google Scholar
• Glickstein H, Breuer W, Loyevsky M, Konijn AM, Shanzer A,Cabantchik ZI. Differential cytotoxicity of iron chelators on malaria-infected cells versus mammalian cells. Blood 1996;87:4871–4878.
   PubMed Web of Science ®Google Scholar
• a-Valle P, Timeus F, Piglione M, Rosso P, di Montezemolo LC, Crescenzio N, Marranca D, Ramenghi U. Effect of different exposures to desferrioxamine on neuroblastoma cell lines. Pediatr Hematol Oncol 1995;12:439–446.
   PubMed Web of Science ®Google Scholar
• Cappellini MD, Cohen A, Piga A, Bejaoui M, Perrotta S, Agaoglu L, Aydinok Y, Kattamis A, Kilinc Y, Porter J, et al. A phase 3 study of deferasirox (ICL670), A once-daily oral iron chelator, in patients with beta-thalassemia. Blood 2006;107:3455–3462.
   PubMed Web of Science ®Google Scholar
• Selig RA, White L, Gramacho C, Sterlinglevis K, Fraser IW, Naidoo D. Failure of iron chelators to reduce tumor growth in human neuroblastoma xenografts. Cancer Res 1998;58:473–478.
   PubMed Web of Science ®Google Scholar
• Olivieri NF, Koren G, Matsui D, Liu PP, Blendis L, Cameron R, McClelland RA, Templeton DM. Reduction of tissue iron stores and normalization of serum ferritin during treatment with the oral iron chelator L1 in thalassemia intermedia. Blood 1992;79:2741–2748.
   PubMed Web of Science ®Google Scholar
• Al-Refaie FN, Wonke B, Hoffbrand AV, Wickens DG, Nortey P, Kontoghiorges GJ. Efficacy and possible adverse effects of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in thalassemia major. Blood 1992;80:593–599.
   PubMed Web of Science ®Google Scholar
• Collins AF, Fassos FF, Stobie S, Lewis N, Shaw D, Fry M, Templeton DM, McClelland RA, Koren G, Olivieri NF. Iron-balance and dose-response studies of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in iron-loaded patients with sickle cell disease. Blood 1994;83:2329–2333.
   PubMed Web of Science ®Google Scholar
• Porter JB, Davis BA. Monitoring chelation therapy to achieve optimal outcome in the treatment of thalassaemia. Best Pract Res Clin Haematol 2002;15:329–368.
   PubMed Web of Science ®Google Scholar
• Lovejoy D, Richardson DR. Novel “,hybrid”iron chelators derived from aroylhydrazones and thiosemicarbazones demonstrate high anti-proliferative activity that is selective for tumor cells. Blood 2002;100:666–676.
   PubMed Web of Science ®Google Scholar
• Bergeron RJ, Wiegand J, McManis JS, Bharti N. The design, synthesis and evaluation of organ-specific iron chelators. J Med Chem 2006;49:7032–7073.
   PubMed Web of Science ®Google Scholar
• Liu ZD, Hider RC. Design of iron chelators with therapeutic application. Coord Chem Rev 2002; 232:151–171.
   Web of Science ®Google Scholar
• Liu ZD, Hider RC. Design of clinically useful iron-selective chelators. Medicinal Res Rev 2002;22:26–64.
   PubMed Web of Science ®Google Scholar
• Sansone F, Segura M, Ungaro R. Calixarenes in Bioorganic and Biomimetic Chemistry. In: Asfari Z, Böhmer V, Harrowfield J, Vicens J, eds. Calixarenes 2001. Dordrecht, The Netherlands: Kluwer Academic Publishers, 2001:496–512.
   Google Scholar
• Mutihac L. Functionalized calix[n]arenes as membrane transporters for biological compounds. A minireview. Curr Drug Discov Technol 2008;5:98–104.
   PubMedGoogle Scholar
• Jose P, Menon S. Lower-rim substituted calixarenes and their applications. Bioinorg Chem Appl 2007:65815.
   Google Scholar
• Gutsche CD. Calixarenes: monographs in supramolecular chemistry, Royal society of Chemistry. London, 1989.
   Google Scholar
• Asfari Z, Böhmer V, Harrowfield J, Vicens J, Calixarene. Dordrecht: Kluwer Academic, 2001.
   Google Scholar
• Guillon J, Léger JM, Sonnet P, Jarry C, Robba M. Synthesis of cone, partial-cone and 1,3-alternate 25,27-bis[1-(2-ethyl)hexyl]- and 25,27-bis[1-(2-tert-butoxy)ethyl]calix[4]arene-crown-6 conformers as potential selective cesium extractants. J Org Chem 2000;65:8283–8289.
   PubMed Web of Science ®Google Scholar
• Guillon J, Sonnet P, Malval JP, Massip S, Gosse I, Léger JM, Lapouyade R, Rochette J, Monti JP, Jarry C. Synthesis and cesium binding affinity of new 25,27-bis(alkyloxy)calix[4]arene-crown-6 conformers in relation to the alkyl pendent moiety. Supramol Chem 2002;14:437–450.
   Web of Science ®Google Scholar
• Guillon J, Léger JM, Dapremont C, Denis LA, Sonnet P, Massip S, Jarry C. First synthesis of 1,3-alternate 25,27-dialkyloxy-5,17-diarylcalix[4]arenes-crown-6 as new cesium selective extracants by Suzuki cross-coupling reaction. Supramol Chem 2004;16:319–329.
   Web of Science ®Google Scholar
• Pires VS, Gaboriau F, Guillon J, Nascimento S, Dassonville A, Lescoat G, Desplat V, Rochette J, Jarry C, Sonnet P. Modulation of cell proliferation in rat liver cell cultures by new calix[4]arenes. J Enzyme Inhib Med Chem 2006;21:261–70.
   PubMed Web of Science ®Google Scholar
• Rouge P, Silva Pires V, Gaboriau F, Dassonville-Klimpt A, Guillon J, Da Nascimento S, Léger JM, Lescoat G, Sonnet P. Antiproliferative effect on HepaRG cell cultures of new calix[4]arenes. J Enzyme Inhib Med Chem 2009;25:216–227.
   Web of Science ®Google Scholar
• Gripon P, Rumin S, Urban S, Le Seyec J, Glaise D, Cannie I, Guyomard C, Lucas J, Trepo C and Guguen-Guillouzo C. Infection of a human hepatoma cell line by hepatitis B virus. Proc Natl Acad Sci USA 2002;99:15655–15660.
   PubMed Web of Science ®Google Scholar
• Troadec MB, Glaise D, Lamirault G, Le Cunff M, Guerin E, Le Meur N, Detivaud L, Zindy P, Leroyer P, Guisle I, Duval H, Gripon P, Theret N, Boudjema K, Guguen-Guillouzo C, Brissot P, Leger JJ and Loreal O. Hepatocyte iron loading capacity is associated with differentiation and repression of motility in the HepaRG cell line. Genomics 2006;87:93–103.
   PubMed Web of Science ®Google Scholar
• Rouan MC, Marfil F, Mangoni P, Sechaud R, Humbert H and Maurer G. Determination of a new oral iron chelator, ICL670, and its iron complex in plasma by high-performance liquid chromatography and ultraviolet detection. J Chromatogr B Biomed Sci Appl 2001;755:203–213.
   PubMed Web of Science ®Google Scholar
• Thomas F, Serratrice G, Beguin C, Aman ES, Pierre JL, Fontecave M, Laulhere JP. Calcein as a fluorescent probe for ferric iron. Application to iron nutrition in plant cells. J Biol Chem 1999;274:13375–13383.
   PubMed Web of Science ®Google Scholar
• Hasinoff BB. The intracellular iron sensor calcein is catalytically oxidatively degraded by iron(II) in a hydrogen peroxide-dependent reaction. J Inorg Biochem 2003;95:157–164.
   PubMed Web of Science ®Google Scholar
• Rodbard D, McClean SW. Automated computer analysis for enzyme multiplied immunological techniques. Clin Chem 1977;23:112–115.
   PubMed Web of Science ®Google Scholar
• Bonache MC, Chamorro C, Velasquez S, De Clercq E, Balzarini J, Rodriguez Barrios F, Gago F, Camarasa MJ, San-Felix A. Improving the antiviral effocoency and selectivity of HIV-1 reverse transcriptase inhibithor TSAO-T by the introduction of functional groups at the N-3 position. J Med Chem 2005;48:6653–6660.
   PubMed Web of Science ®Google Scholar
• Mallia MB, Subramanian S, Mathur A, Sarma HD, Venkatesh M, Banerjee S. On the isolation and evaluation of a novel unsubstituted 5-nitroimidazole derivative as an agent to target tumor hypoxia. Bioorg Med Chem Lett 2008;18:5233–5237.
   PubMed Web of Science ®Google Scholar
• Gutsche CD, Lee-Gin L. Calixarenes 12. The synthesis of functionalized calixarenes. Tetrahedron 1986;42:1633–1640.
   Web of Science ®Google Scholar
• Casnati A, Arduini A, Ghidini E, Pochini A, Ungaro R. A general synthesis of calix[4]arene monoalkyl ethers. Tetrahedron 1991;47:2221–2228.
   Web of Science ®Google Scholar
• Berg SS, Newbery G. Chemotherapeutic amidines. X. Substituted 4,4'-diamidino-ω,ω-diphenoxyalkanes and –diphenylethers. J Chem Soc 1949;642–648.
   Web of Science ®Google Scholar
• Barboso S, Garcia Carrera A, Matthews SE, Arnaud-Neu F, Böhmer V, Dozol JF, Rouquette H, Schwing-Weill MJ. Calix[4]arenes with CMPO functions at the narrow rim. Synthesis and extraction properties. J Chem Soc, Perkin Trans 2 1999;4:719–723.
   Google Scholar
• Rudzevich Y, Rudzevich V, Moon C, Schnell I, Fischer K, Böhmer V. Self-assembly of programmed building blocks into structurally uniform dendrimers. J Am Chem Soc 2005;127:14168–14169.
   PubMed Web of Science ®Google Scholar
• Clark TE, Makha M, Raston CL, Sobolev AN. Supersized bilayers based on an O-alkyl substituted calix[4]arene. CrystEngComm 2006;8:707–711.
   Web of Science ®Google Scholar
• Ismail MA, Arafa RK, Brun R, Wenzler T, Miao Y, Wilson WD, Generaux C, Bridges A, Hall JE, Boykin DW. Synthesis, DNA affinity, and antiprotozoal activity of linear dications: terphenyl diamidines and analogues. J Med Chem 2006;49:5324–5332.
   PubMed Web of Science ®Google Scholar
• Dalai S, Belov VN, Nizamov S, Rauch K, Finsinger D, de Meijere A. Access to Variously Substituted 5,6,7,8-Tetrahydro-3H-quinazolin-4-ones via Diels-Alder Adducts of Phenyl Vinyl Sulfone to Cyclobutene-Annelated Pyrimidinones. Eur J Org Chem 2006;12:2753–2765.
   Web of Science ®Google Scholar
• Ismail MA, Arafa RK, Wenzler T, Brun R, Tanious FA, Wilson WD, Boykin DW. Synthesis and antiprotozoal activity of novel bis-benzamidinoimidazo[1,2-a]pyridines and 5,6,7,8-tetrahydroimidazo[1,2-a]pyridines. Bioorg Med Chem 2008;16:683–691.
   PubMed Web of Science ®Google Scholar
• Supplementary X-ray crystallographic data of compounds 1, 2 and 3 (CCDC-748460, CCDC-748458 and CCDC-748459): Cambridge Crystallographic Data Centre, University Chemical Lab, 12 Union Road, Cambridge, CB2 1EZ, UK; E-mail: [email protected].
   Google Scholar